Annovis Bio, Inc. Cash Flow Statement
ANVS|6 years of annual SEC 10-K data (FY2020-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
Annovis Bio, Inc. used $26M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -9.28 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income | -$28.9M | -$56.2M | -$25.3M | -$25.3M | -$5.5M | -$991.0K |
| Operating Cash Flow | -$25.6M | -$40.0M | -$17.3M | -$17.3M | -$4.0M | -$476.5K |